论文部分内容阅读
目的:探讨ALDH1和CD55蛋白在正常卵巢组织、卵巢良性肿瘤组织及卵巢上皮性癌组织中的表达及其与临床病理特征的关系。方法:采用免疫组织化学法检测ALDH1和CD55蛋白在20例正常卵巢组织、20例卵巢良性肿瘤组织及60例卵巢上皮性癌组织中的表达。结果:ALDH1和CD55蛋白在卵巢上皮性癌组织中的表达明显高于正常卵巢组织和卵巢良性肿瘤组织(P<0.01),并且ALDH1和CD55蛋白的表达随组织病理分级的升高而升高(P<0.05),随手术病理分期的升高而升高(P<0.05),但在不同组织学类型中的表达无统计学差异(P>0.05)。结论:ALDH1和CD55蛋白的表达在卵巢上皮性癌的发生、发展中具有重要作用,可能成为诊断卵巢上皮性癌新的生物标志物,可以判断其生物学行为、预测转移趋势及预后。
Objective: To investigate the expression of ALDH1 and CD55 protein in normal ovarian tissue, benign ovarian tumor and epithelial ovarian cancer and its relationship with clinicopathological features. Methods: The expressions of ALDH1 and CD55 in 20 cases of normal ovarian tissue, 20 cases of benign ovarian tumor and 60 cases of ovarian epithelial carcinoma were detected by immunohistochemistry. Results: The expression of ALDH1 and CD55 protein in epithelial ovarian cancer was significantly higher than that in normal ovarian tissue and benign ovarian tumor (P <0.01), and the expression of ALDH1 and CD55 protein increased with the increase of histopathological grade P <0.05). The pathological stage of the operation increased with the rise (P <0.05), but there was no significant difference in different histological types (P> 0.05). Conclusion: The expression of ALDH1 and CD55 proteins plays an important role in the occurrence and development of epithelial ovarian cancer, and may be a new biomarker for the diagnosis of epithelial ovarian cancer. The biological behavior of ALDH1 and CD55 may be evaluated and the prognosis of metastasis and prognosis may be predicted.